Cardiket

Quick links to important sections

Cardiket

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardiket

Quick Facts

Property Description
Active ingredient Isosorbide Dinitrate (ISDN)
Form Tablet (Oral, Sustained-release, Sublingual)
Pharmacological class Vasodilator, Anti-anginal agent
General purpose Reducing cardiac workload and increasing heart oxygen supply
Origin Synthetic compound (Organic nitrate)

What Type of Medicine is Cardiket? (Identity and Classification)

Cardiket is a specialized prescription-only medicine that is clinically recognized as an effective anti-anginal agent and a potent vasodilator. Its core therapeutic function is derived from its active substance, Isosorbide Dinitrate (ISDN), placing it within the chemical family of organic nitrates. The drug's mechanism of reducing vascular resistance is supported by pharmacological studies, confirming its vital role among Nitrate Vasodilators. Its purpose is to influence the vascular system for sustained circulatory support, making it a key component in long-term management strategies.

Composition, Origin, and Available Forms (Structure and Variation)

The active ingredient, Isosorbide Dinitrate, is a synthetic compound that operates as a single-ingredient product in Cardiket formulations. The drug is primarily manufactured into various pharmaceutical preparations, including the standard oral tablet, the sustained-release tablet, and the distinctive sublingual tablet. These forms permit different routes of administration (oral and sublingual), with the latter allowing for rapid absorption to address transient needs. The formulation's stability is dependent on the blend of the active ingredient and necessary pharmaceutical excipients, confirming quality control in its production.

Cardiket’s General Therapeutic Purpose

The overall therapeutic purpose of Cardiket is to alleviate strain on the heart muscle by inducing widespread smooth muscle relaxation throughout the vascular system. This function is critical for individuals requiring support for improved cardiac efficiency and circulatory comfort. The resultant vasodilation works by reducing the volume of blood returning to the heart (preload) and lessening the resistance the heart must pump against (afterload), thereby reducing the heart’s workload. This mechanism provides a typical benefit in scenarios where the heart requires consistent relief from excessive strain.

Regulatory References

  1. Organic Nitrates
  2. Nitrate Vasodilators
  3. afterload

What side effects are possible with Cardiket?

Possible Side Effects and Safety Information

The officially documented adverse reaction profile for Isosorbide Dinitrate is characterized by effects primarily related to its mechanism as a vasodilator, with adverse reactions formally categorized by frequency in regulatory sources.

Adverse Reaction Frequencies

Classification Examples of Officially Documented Effects
Very Common Headache (most frequently reported side effect)
Common Dizziness, Tachycardia (increased heart rate), Hypotension (low blood pressure)
Uncommon Nausea, Vomiting, Facial Flushing, Syncope (fainting)
Very Rare Angioedema, Stevens-Johnson syndrome, Circulatory Collapse (shock)

Systems Affected and Safety Patterns

Adverse reactions are formally grouped into system-organ classes, including Nervous System Disorders (e.g., headache, dizziness), Vascular Disorders (e.g., hypotension, flushing), and Cardiac Disorders (e.g., tachycardia, aggravation of angina pectoris).

Regulatory documents explicitly note a time-related safety pattern, stating that headache and dizziness are more frequent at the start of treatment or during initial dose increases. The severity of the headache often diminishes with continued use.

High-Level Safety Constraints

The label documents specific, severe safety consequences related to high-level restrictions. Co-administration of the active substance with phosphodiesterase type 5 (PDE5) inhibitors is strictly associated with a risk of profound hypotension and circulatory collapse. Additionally, the official safety profile notes that anti-anginal efficacy is tied to a daily dose-free interval to minimize the development of pharmacological tolerance.

Overdose and Emergency Response

Overdose and when to seek help

Overdose from Isosorbide Dinitrate is officially documented as primarily causing massive vasodilation, resulting in a severe drop in blood pressure and potential circulatory collapse. The official regulatory profile notes that overdose may present with signs in the Cardiovascular, Central Nervous System, and Hematological systems.

Documented manifestations include severe throbbing headache, confusion, vertigo, restlessness, and syncope (fainting). Cardiovascular signs listed are severe hypotension, tachycardia, and potentially a paradoxical bradycardia. Systemic signs like cyanosis (bluish skin discoloration) and cold, clammy skin may also occur.

A severe, life-threatening outcome documented in regulatory sources is methaemoglobinaemia, a condition impairing oxygen delivery that may lead to seizures or coma. For this specific complication, the label-recognized antidote is Methylene Blue.

When Immediate Medical Help is Required

For any suspected overdose or experience of severe symptoms, official regulatory guidance mandates that users seek immediate medical attention and contact emergency medical services or a poison control center right away. Management requires stopping the drug and administering supportive measures like intravenous fluids to expand central fluid volume. If the patient is dizzy or faint, they should sit or lie down with their legs passively elevated while emergency help is sought. Continuous cardiac monitoring and monitoring of methemoglobin concentration are required in severe cases.

Therapeutic Uses of Cardiket

Cardiket is indicated for the acute relief of chest pain and associated discomfort experienced during angina pectoris episodes. It serves a therapeutic role in managing the symptoms of stable exertional angina and unstable angina.

It is also an option for the long-term management of chronic coronary artery disease. When used prophylactically, it may help reduce the occurrence of anginal episodes, assisting patients in supporting their exercise capacity and overall comfort.

This medication is a component of comprehensive treatment for these cardiovascular conditions.

Quick Fact: Relief for Chest Discomfort

Eligibility and Restrictions for Use

Cardiket (Isosorbide Dinitrate) is officially authorized for use in the adult population for treating or preventing angina pectoris. However, regulatory documents establish strict prohibitions and conditions for other patient groups.

Eligibility Scope

Classification Status According to Regulatory Labeling
Populations for Whom Use is Allowed Adults (age 18 and over)
Populations for Whom Use is Not Recommended Patients with recent acute myocardial infarction; use in geriatric patients is conditional due to insufficient data for this age group.
Pediatric Use (Under 18) Safety and effectiveness have not been established. Use is not authorized by some regulatory agencies.

Populations for Whom Use is Contraindicated

Cardiket must not be used by the following groups due to the risk of severe, life-threatening hypotension:

  • Patients with a known hypersensitivity to organic nitrates or any component of the formulation.
  • Patients concurrently taking Phosphodiesterase type 5 (PDE5) inhibitors (e.g., sildenafil, tadalafil).
  • Patients concurrently taking the soluble guanylate cyclase (sGC) stimulator riociguat.
  • Individuals experiencing cardiogenic shock or marked hypotension (e.g., systolic blood pressure below 90 mmHg).
  • Patients with obstructive cardiomyopathy or increased intracranial pressure.

Pregnancy and Lactation Eligibility Status

  • Pregnancy: Use is generally conditional (FDA Category C). It should be used only if the potential benefit justifies the potential risk to the fetus.
  • Lactation: It is not known if the drug is excreted in human milk; caution is advised when administering it to a nursing mother.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction patterns of Cardiket (Isosorbide Dinitrate) as established by government regulatory authorities.

Absolute Contraindications and Restrictions

Co-administration of Cardiket with Phosphodiesterase-5 (PDE-5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) is strictly prohibited. This restriction is due to an absolute contraindication arising from the risk of severe, life-threatening hypotension. Similarly, concomitant use with Soluble Guanylate Cyclase (sGC) Stimulators (e.g., Riociguat) is also contraindicated due to the potential for potentiating hypotensive effects. Mandatory timing rules exist: acute administration of Cardiket must be separated by at least 24 to 48 hours from the last dose of certain PDE-5 inhibitors.

Clinically Significant Interactions

Pharmacodynamic Interactions: Cardiket exhibits additive hypotensive effects when co-administered with other blood pressure lowering agents, including beta-blockers, ACE-inhibitors, and other vasodilators. Alcohol consumption may also potentiate the vasodilating and hypotensive effects of the medicine. Co-administration with Dihydroergotamine is noted for potentially increasing the hypertensive effect of Dihydroergotamine.

Metabolic and Exposure Modification: Strong inducers of the CYP3A4 enzyme may reduce the plasma exposure of Cardiket. Conversely, strong inhibitors of CYP3A4 may increase systemic exposure, increasing the risk of adverse effects as defined in regulatory summaries.

Mechanism of Action

Molecular Conversion to Nitric Oxide and cGMP Signaling

The mechanism is initiated by the bioactivation of the compound within vascular smooth muscle, where Isosorbide Dinitrate (ISDN) is converted by reductase enzymes (e.g., ALDH-2) to release Nitric Oxide (NO). The NO acts as an endogenous chemical messenger, binding to and activating the cytosolic enzyme soluble Guanylyl Cyclase (sGC). This critical interaction significantly increases the intracellular concentration of the second messenger cyclic Guanosine Monophosphate (cGMP), which initiates the cell's relaxation sequence. This process utilizes an existing humoral pathway to modulate vascular tone.


Targeted Relaxation and Hemodynamic Modulation

The elevated cGMP level ultimately causes the dephosphorylation of the Myosin Light Chain, resulting in the physical relaxation of the vascular smooth muscle. This leads to widespread vasodilation, preferentially affecting the large venous capacitance vessels. The primary physiological consequence is a reduction in venous return, which lowers the pressure and volume load on the heart's ventricles (preload). Simultaneously, vasodilation of the systemic arterioles reduces the pressure the heart pumps against (afterload). This combined hemodynamic effect leads to a reduction in the workload on the heart muscle, resulting in a corresponding decrease in its oxygen and energy demand.

Dosage and Administration Information

How Cardiket is Used: Administration Guidelines

Cardiket (Isosorbide Dinitrate) is administered via the oral route (as immediate-release or extended-release tablets) or sublingually (under the tongue). The intravenous route for the active substance is reserved for acute, professionally supervised settings. Correct usage relies on adherence to the specific dose, frequency, and administration technique to maintain effectiveness.


Standard Dosing and Scheduling

Administration Route Typical Adult Dosing Frequency and Timing
Oral (Immediate-Release) Initial dose: 5 mg to 20 mg. Maintenance: 10 mg to 40 mg. Two or three times daily. Must include a daily dose-free interval to prevent tolerance.
Oral (Extended-Release) Generally 40 mg to 80 mg daily. Once or twice daily. Must incorporate a long dose-free interval.
Sublingual 2.5 mg to 5 mg as needed. Used prior to anticipated physical or emotional stress.

Administration Requirements and Precautions

  • Nitrate-Free Interval: All long-term oral regimens must incorporate a daily dose-free period of at least 14 hours to minimize the development of drug tolerance, a critical procedural rule.
  • Intake Technique: Extended-release tablets must be swallowed whole and must not be crushed, chewed, or split. Sublingual tablets must be placed under the tongue and allowed to dissolve completely; they cannot be swallowed.
  • Older Adults (Geriatric Use): Dosing should begin cautiously at the low end of the range due to the higher frequency of decreased organ function.
  • Missed Dose: If a dose is missed, it is generally advised to take the next dose at the regularly scheduled time. Double doses should not be taken to compensate for a missed dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Cardiket

Research for Acute Relief of Angina Symptoms

Research exploring the study of Cardiket (Isosorbide Dinitrate) for episodic symptoms centers on short-term, randomized controlled trials (RCTs) in adults with stable angina. These studies examine outcomes related to physical discomfort and functional activity level shortly after administration, monitoring physiological strain during exercise testing. Research describes patterns of rapid onset and how symptoms changed over defined time intervals. The findings provide context for the effect being studied, though long-term impact for repeated acute use remains unclear.


Research for Long-Term Management of Angina

The research base for long-term use relies on intermediate- to long-term RCTs evaluating patterns in anginal episode frequency and functional activity level. Studies explore formulations and dosing schedules to reduce the weekly frequency of episodes and maintain physical exercise capacity. Research reports patterns related to the maintenance of activity level; however, a key challenge studied is the potential for the measured functional response to attenuate over time (nitrate tolerance) with continuous use.


Research for Use in Chronic Heart Failure (Adjunct Therapy)

Cardiket was evaluated in large-scale, long-term RCTs for adjunct treatment in chronic heart failure, particularly when used in a combination regimen with hydralazine. Research explored outcomes related to all-cause mortality and rates of hospitalization for heart failure events in adults with reduced cardiac pumping ability. Findings describe patterns related to sustained outcomes in specific heart failure patient groups. However, evidence remains limited for the use of Cardiket as a monotherapy, and data for those with preserved ejection fraction (HFpEF) remain limited.


Evidence Gaps and Special Populations

Evidence in specific groups, such as pediatric or pregnant patients, remains insufficient. Comparative evidence for older adults with multiple comorbidities also remains limited. A central area of research focuses on better understanding and managing nitrate tolerance in long-term angina use. Findings describe group patterns, not personal outcomes, and highlight what is known and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Cardiket (FAQ)


Q: How quickly should I expect Cardiket to start working?

A: The speed at which Cardiket takes effect depends on the specific form of the tablet. Sublingual tablets, which are placed under the tongue, are designed for rapid dissolution and are intended to be used prior to anticipated physical or emotional stress, according to regulatory guidelines. In contrast, the immediate-release oral tablets have a slower onset.


Q: Is Cardiket the same as isosorbide mononitrate?

A: No, they are related but distinct medicines. Cardiket’s active ingredient is Isosorbide Dinitrate (ISDN). Isosorbide Mononitrate (ISMN) is a separate type of organic nitrate often used for similar purposes. Official information notes that ISMN is also the primary active substance the body forms when it processes ISDN.


Q: What foods or drinks should be avoided while taking Cardiket?

A: Regulatory documents advise that alcohol consumption should be limited while taking Cardiket. This is because alcohol may increase the vasodilating effects of the medicine, potentially leading to increased hypotension (low blood pressure). Official warnings generally do not list restrictions for specific foods.


Q: Does Cardiket affect blood pressure readings?

A: Yes. Cardiket is classified as a vasodilator, meaning its intended therapeutic action is to relax blood vessels, which consequently helps to lower blood pressure. A reduction in blood pressure is expected as part of its effect, and hypotension (low blood pressure) is also listed in official sources as a common side effect.


Q: Are there any specific safety warnings for people with liver problems using Cardiket?

A: While specific warnings for severe liver (hepatic) impairment are not detailed in standard prescribing information, official labels mention that dosing caution is warranted for older adults due to the potential for decreased overall organ function.


Q: Does Cardiket affect a person's ability to drive?

A: Cardiket can affect the ability to drive or operate machinery. Official prescribing information advises that patients should be cautious or refrain from driving or operating machinery until they are aware of how the drug affects their body, due to side effects like dizziness, lightheadedness, and syncope (fainting).


Q: Can Cardiket interact with supplements or herbal remedies?

A: Official documents focus on interactions with prescription medications and known enzyme pathways. It is generally recognized that official safety guidance recommends informing a healthcare provider about all medicines, including supplements and herbal remedies, to allow for a comprehensive review of potential interactions.


Q: Is it dangerous to stop taking Cardiket suddenly?

A: Official patient information indicates that abrupt discontinuation of Cardiket, particularly after regular long-term use, may result in a return or a worsening of angina symptoms. This is why abrupt stopping is generally advised against.


Q: Can Cardiket make me feel more tired than usual?

A: General tiredness or fatigue is not typically listed among the common side effects of Cardiket in regulatory documents. However, feelings of weakness or being unusually tired can be a symptom associated with the common side effect of hypotension (low blood pressure).


Q: Is Cardiket considered a blood thinner?

A: No. Cardiket is classified as an Anti-anginal Agent and a Vasodilator. Its function is to relax the blood vessels to reduce the heart's workload, but it does not thin the blood or prevent clotting like anticoagulant or antiplatelet medicines.


Q: Is Cardiket ever used for conditions other than heart problems?

A: Cardiket is officially authorized for the treatment and prevention of angina pectoris and for use in specific combination regimens for chronic heart failure. Regulatory documents do not authorize its use for other conditions.


Q: Why is Cardiket sometimes referred to as a prophylactic treatment?

A: It is referred to as a prophylactic treatment because, according to its indications, Cardiket is officially used for the prevention of angina pectoris attacks, meaning it is taken to stop symptoms before they occur, which aligns with the definition of prophylaxis.


Q: Does the dose of Cardiket need adjustment over time?

A: Regulatory dosing guidelines indicate that doses are often started low and adjusted based on the individual's needs and clinical response. A crucial aspect of long-term adjustment is the need to ensure a daily 'nitrate-free interval' to prevent the body from developing tolerance to the medicine's effects.


Q: Does Cardiket cause changes in mood or anxiety?

A: Official adverse reaction documents list effects on the nervous system, such as headache and dizziness, as common occurrences. However, specific changes in mood or anxiety are generally not listed as commonly or frequently reported side effects.


Q: Is Cardiket available in different strengths?

A: Yes. Cardiket, or its generic equivalent Isosorbide Dinitrate, is manufactured in multiple dosage strengths for both the oral and sublingual forms. This allows for individualized prescribing to address different therapeutic needs.


Q: Is there research on Cardiket use in people with kidney disease?

A: Official prescribing information indicates that patients with severe kidney (renal) impairment may require cautious dosing and close monitoring due to potential sensitivity to the blood pressure-lowering effects of the medicine.


Q: Are there specific checks a doctor performs before prescribing Cardiket?

A: Doctors must check for conditions that represent absolute contraindications before prescribing. These include marked hypotension (very low blood pressure), certain heart conditions like cardiogenic shock, and concurrent use of specific prohibited medications, such as PDE5 inhibitors.


Q: Can Cardiket be used by people with asthma?

A: Asthma or other common respiratory conditions are generally not listed in official regulatory documents as a specific contraindication or precaution for the use of Cardiket, unlike for some other cardiac medicines.


Q: Is Cardiket a generic or brand-name drug?

A: Cardiket is a brand name for the drug. The generic name for the active ingredient contained in the tablets is Isosorbide Dinitrate.


Q: Is Cardiket described as having a high potential for drug dependence?

A: No. Cardiket is not generally classified as a controlled substance by regulatory agencies. Official safety information does not describe this medicine as having a high potential for drug dependence or misuse.

How should Cardiket be stored and disposed of?

How to Store and Dispose of Cardiket?

Cardiket (Isosorbide Dinitrate) must be stored according to official regulatory requirements to ensure product stability and potency.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Must be stored away from excessive heat, and protected from both light and moisture.
Container Keep the medicine in its original container, and ensure it remains tightly closed.
Child Safety The product must be kept out of the sight and reach of children.

Disposal Instructions

Unused or outdated medicine must be disposed of following local governmental regulations. Patients are instructed to consult a healthcare professional for guidance on the proper method for discarding any unused product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardiket found in:

A-Z Index: